SAN DIEGO , March 23, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the 17th Annual Needham Healthcare Conference on Tuesday, March 27 at 3:00 p.m.
SAN DIEGO , March 21, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the pricing of an underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $41.50 per share. All of the shares are being sold by Arena.
SAN DIEGO , March 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, 7,500,000 shares of its common stock in an underwritten public offering. Arena expects to grant the underwriters an option
- OASIS trial met primary and all secondary endpoints with statistical significance for patients receiving 2 mg dose of etrasimod for 12 weeks - The 2 mg etrasimod group achieved statistically significant improvement in clinical remission - Safety results support potential best-in-class profile -
- Etrasimod Phase 2 Data in UC Anticipated this Month - Ralinepag Phase 3 Clinical Program Expected to Begin in H2 2018 SAN DIEGO , March 14, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today provided a corporate update and reported financial results for the fourth quarter and
SAN DIEGO , March 8, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), will announce its fourth quarter and full-year 2017 financial results on Wednesday, March 14, 2018 , before the open of the U.S. financial markets. The Company will host a conference call and live webcast to
- Data from Phase 1 study of APD371 in healthy volunteers demonstrate safety and tolerability - Healthy volunteers did not exhibit psychotropic effects commonly seen with cannabinoids - Preclinical studies show thousand-fold selectivity for CB2 over CB1 receptors SAN DIEGO , March 1, 2018
SAN DIEGO , Feb. 16, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced Scott H. Bice, Phillip M. Schneider , and Christine A. White , M.D. have indicated that they will be retiring from the Board of Directors at the time of Arena's next annual stockholders' meeting,
SAN DIEGO , Feb. 6, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that that members of its senior management team will present at two upcoming investor conferences in New York City . LEERINK Partners 7 th Annual Global Healthcare Conference - Presenting on